1 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion.

Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, Ying Chen, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters. 1 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion. . 2021 Mar 1; 27(3):s1.

2021
https://researcherprofiles.org/profile/177941495

Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, Ying Chen, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters